Delving into the Latest Updates on L-Arginine hydrochloride/L-Lysine hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Arginine/Lysine, L-Arginine Hydrochloride / L-Lysine Hydrochloride, L-Lysine HCl/L-Arginine HCl

+ [5]

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Radiation Injuries

Inactive Indication-

Originator Organization

Advanced Accelerator Applications SA

Active Organization

FUJIFILM Toyama Chemical Co., Ltd.

Advanced Accelerator Applications SA

Novartis Pharma KK

+ [1]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

European Union (25 Jul 2019),

Radiation Injuries

RegulationOrphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Molecular FormulaC6H15ClN4O2

InChIKeyKWTQSFXGGICVPE-WCCKRBBISA-N

CAS Registry1119-34-2

View All Structures (2)

The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide Receptor (GRPR) between the start and after the completion of radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC).

Start Date29 Jul 2024

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

IRCT20230603058376N1

/ RecruitingPhase 1IIT

Evaluation of the effect of arginine administration on height growth of Children in lower limit range

Start Date11 Oct 2023

Sponsor / Collaborator

Ardabil University of Medical Sciences

IRCT20230728058947N1

/ RecruitingPhase 2IIT

Investigating the amount of salivary pH changes following the use of arginine mouthwash: a randomized clinical trial

Start Date01 Aug 2023

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

100 Clinical Results associated with L-Arginine hydrochloride/L-Lysine hydrochloride

Login to view more data

100 Translational Medicine associated with L-Arginine hydrochloride/L-Lysine hydrochloride

Login to view more data

100 Patents (Medical) associated with L-Arginine hydrochloride/L-Lysine hydrochloride

Login to view more data

11

Literatures (Medical) associated with L-Arginine hydrochloride/L-Lysine hydrochloride

01 Nov 2023·Amino Acids

Shuttle between arginine and lysine: influence on cancer immunonutrition

Review

Author: Prasad, Shashanka K ; Sindhu, R ; Supreeth, M ; Thanmaya, M

Amino acids which are essential nutrients for all cell types' survival are also recognised to serve as opportunistic/alternative fuels in cancers auxotrophic for specific amino acids. Accordingly, restriction of amino acids has been utilised as a therapeutic strategy in these cancers. Contrastingly, amino acid deficiencies in cancer are found to greatly impair immune functions, increasing mortality and morbidity rates. Dietary and supplemental amino acids in such conditions have revealed their importance as 'immunonutrients' by modulating cellular homeostasis processes and halting malignant progression. L-arginine specifically has attracted interest as an immunonutrient by acting as a nodal regulator of immune responses linked to carcinogenesis processes through its versatile signalling molecule, nitric oxide (NO). The quantum of NO generated directly influences the cytotoxic and cytostatic processes of cell cycle arrest, apoptosis, and senescence. However, L-lysine, a CAT transporter competitor for arginine effectively limits arginine input at high L-lysine concentrations by limiting arginine-mediated effects. The phenomenon of arginine-lysine antagonism can, therefore, be hypothesised to influence the immunonutritional effects exerted by arginine. The review highlights aspects of lysine's interference with arginine-mediated NO generation and its consequences on immunonutritional and anti-cancer effects, and discusses possible alternatives to manage the condition. However, further research that considers monitoring lysine levels in arginine immunonutritional therapy is essential to conclude the hypothesis.

01 Mar 2022·Current Radiopharmaceuticals

Comparison of Two Types of Amino Acid Solutions on 177Lu-Dotatate Pharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Article

Author: Brillouet, Séverine ; Chatelut, Etienne ; Courbon, Frédéric ; Dierickx, Lawrence ; Lambert, Marie

Background:177Lu-Dotatate is used in the treatment of somatostatin-receptor-positive inoperable progressive gastroenteropancreatic neuroendocrine tumors. A co-infusion of amino acids (AAs) is administered to prevent renal toxicity.Objective:This study aimed to quantify the impact of two types of AA cocktails on the pharmacokinetics and toxicity of 177Lu-Dotatate.Method:Four injections of 7400 MBq 177Lu-Dotatate were given per patient with administration of either Primene® 10% (containing a cocktail of 20 AAs with 22g of Lysine and 16.8 g of Arginine) or Lysakare® (containing 25 g of Lysine and 25 g of Arginine). Nine blood samples were collected at each cycle. Radioactivity-time data were analyzed according to a population-based model using NONMEM (version 7.4.1). Renal and hematological toxicity was evaluated after each cycle.Result:1,678 177Lu-Dotatate plasma concentrations versus time were analyzed from 83 consecutive patients with Primene® (n= 45 pts) or Lysakare® (n= 36 pts). Population pharmacokinetic analysis showed that Primene® significantly increased the elimination rate constant of 177Lu-Dotatate as opposed to Lysakare®. Primene® also significantly lowered Lutathera® plasma exposure (AUC) by 34%, whereas Lysakare® increased AUC by 7%. There was no renal toxicity in either case. Lymphopenia significantly correlated with AUC (p=0.021) with a trend towards higher toxicity with Lysakare®.Conclusions::Unlike Primene®, Lysakare® does not increase 177Lu-Dotatate elimination. This difference is associated with a significant impact on AUC. The latter parameter has a high interpatient variability but a low intrapatient variability, which could have important clinical implications for treatment tailoring.

01 Mar 1998·Brain Research BulletinQ3 · MEDICINE

Influence of systemic arginine-lysine on immune organ function: An electrophysiological study

Q3 · MEDICINE

Article

Author: Michael M Meguid ; Akira Niijima

To test our hypothesis that arginine (Arg) and lysine (Lys) enhance immune activities via neuronal control of the thymus and the spleen, a jugular vein was cannulated for amino acid administration in male Wistar rats (approximately 300 g). In one group (n = 5), an efferent nerve filament of the vagal thymus was isolated. In another group (n = 5), splenic nerve efferents were isolated. Efferent firing rates were recorded before and for 60-90 minutes after 10 mM Arg-Lys in 0.5 ml saline intravenously (i.v.). Differences in firing rates were evaluated using analysis of variance (ANOVA) and t-test. I.v. Arg-Lys increased vagal efferent firing rate to the thymus; enhancing thymic lymphocyte release. I.v. Arg-Lys decreased firing rate in splenic efferents; enhancing natural killer (NK) cell activity. Therefore, Arg-Lys are detected by hepatoportal sensors, stimulating hepatic vagal afferents to the hypothalamus, with the efferent neuronal impulses from the hypothalamus modulating immune function in thymus and spleen, thereby demonstrating the mechanism of Arg and Lys immune enhancing activity.

100 Deals associated with L-Arginine hydrochloride/L-Lysine hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V03AF11	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Radiation Injuries	Iceland	Advanced Accelerator Applications SA	25 Jul 2019
Radiation Injuries	Norway	Advanced Accelerator Applications SA	25 Jul 2019
Radiation Injuries	European Union	Advanced Accelerator Applications SA	25 Jul 2019
Radiation Injuries	Liechtenstein	Advanced Accelerator Applications SA	25 Jul 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04524442 (CTgov)	Phase 4	Gastro-Enteropancreatic Neuroendocrine Tumor	42	arginine/lysine	sywhslfpez(copsmnfrmk) = filehlugqq maeajqcugg (mkgeqeqipw, qzwkbeswck - rvtxrbnhce) View more	-	24 Jan 2025